---
title: "AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: SynAIRgy"
description: "Formulary evidence on AD109 (aroxybutynin-atomoxetine, Oxnimbi) in Obstructive sleep apnea: SynAIRgy. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 106 evidence topics quoted from 17 sources."
canonical: "https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence/synairgy"
published: "2026-11-18T10:43:47-05:00"
modified: "2026-11-18T10:43:47-05:00"
---

# AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: SynAIRgy

<a id="heading-3.1.1"></a>

## 3.1.1 SynAIRgy

<a id="heading-3.1.1.1"></a>

### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

#### Trial objective as stated in the publication

> “To evaluate the efficacy/safety of AD109 over 6 months in a diverse OSA population unable to use PAP.”
> “We conducted the phase 3 SynAIRgy clinical trial to evaluate the efficacy, safety, and tolerability of AD109 vs placebo over 6 months in adults with mild-to-severe OSA who were intolerant to or refused PAP therapy.”

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

<a id="topic-3.1.1.1-2"></a>

#### Primary and secondary objectives in the design paper

> “The primary objective of the LunAIRo and SynAIRgy trials is to demonstrate the efficacy of AD109 versus placebo for upper airway obstruction, as measured by the AHI4, among individuals across the full range of OSA severity, from mild to very severe, over a 26-week treatment period.”
> “Secondary objectives are to demonstrate efficacy of AD109 vs placebo on OSA symptoms including fatigue, one of the most common and bothersome OSA symptoms [[13], [14], [15]], and on measures of oxygenation which have been shown to correlate more strongly than AHI with adverse cardiovascular outcomes [16].”
> “Exploratory objectives for both trials involve in-depth examination of the effects of AD109 on sleep parameters, and additional measures of airway obstruction.”

Source: [Taranto-Montemurro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12490522/)

<a id="heading-3.1.1.2"></a>

### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

#### Sites and countries

> “conducted at 69 sites in the United States and Canada”
> “Additionally, trial sites were limited to the United States and Canada and may not fully represent OSA in other geographies.”

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

> “The trial enrolled 646 adult participants from 69 centers in the United States and Canada.”

Source: [Apnimed SynAIRgy publication release (2026)](https://ir.apnimed.com/news-releases/news-release-details/apnimed-announces-publication-its-phase-3-synairgy-trial-ad109)

> “We conducted our SynAIRgy clinical trial with some study sites located in Canada”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-3.1.1.2-2"></a>

#### Number of centers, May to October 2025, superseded in May 2026

> “The trial enrolled 646 adult participants from 73 centers in the US and Canada.”

Source: [Apnimed SynAIRgy topline release (2025)](https://apnimed.com/article/ad109phase3toplineresults/)

> “A total of 64 sites have been identified in the U.S. for LunAIRo (Supplemental Table 1) and 73 sites have been identified in both the U.S. and Canada for SynAIRgy (Supplemental Table 2).”

Source: [Taranto-Montemurro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12490522/)

<a id="topic-3.1.1.2-3"></a>

#### Enrollment period

> “Between December 20, 2023 and March 26, 2025, 646 participants with mild-to-severe OSA were enrolled and randomized to receive AD109 (n = 324) or placebo (n = 322) (Figure 1).”

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

> “We initiated the LunAIRo and SynAIRgy Phase 3 clinical trials for AD109 in September and November of 2023, respectively.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-3.1.1.2-4"></a>

#### Registry study dates

| Field | Quoted record |
| --- | --- |
| Study start (actual) | “2023-09-16” |
| Primary completion (actual) | “2025-03-10” |
| Study completion (actual) | “2025-03-14” |
| Enrollment (actual) | “646” |

Source: [ClinicalTrials.gov NCT05813275](https://clinicaltrials.gov/study/NCT05813275)

<a id="topic-3.1.1.2-5"></a>

#### Registry results posting dates

| Field | Quoted record |
| --- | --- |
| Results first submitted | “2026-08-18” |
| Results first posted | “2026-09-11” |

Source: [ClinicalTrials.gov NCT05813275 results](https://clinicaltrials.gov/study/NCT05813275?tab=results)

<a id="heading-3.1.1.3"></a>

### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

#### Randomized, double-blind, placebo-controlled parallel-arm design

> “SynAIRgy (APC-APN-305; NCT05813275)35 was a phase 3, randomized, double-blind, placebo-controlled, 6-month parallel-arm study of AD109 (Figure S1), conducted at 69 sites in the United States and Canada in compliance with the Declaration of Helsinki and Good Clinical Practice guidelines outlined by the International Council for Harmonisation.”
> “Eligible participants were randomized 1:1 to receive AD109 or placebo and stratified according to baseline AHI (<15, 15 to <30, ≥30 events/hour) and PROMIS-Fatigue T-score (<58.5 vs ≥58.5).”

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

<a id="topic-3.1.1.3-2"></a>

#### Registry design record

| Field | Quoted record |
| --- | --- |
| Official title | “Phase 3 Randomized Double-Blind Placebo-Controlled 6-month Parallel-Arm Study to Compare a Fixed Dose Combination of Aroxybutynin/Atomoxetine (AD109) to Placebo in Obstructive Sleep Apnea (SynAIRgy Study)” |
| Allocation | “Randomized” |
| Intervention model | “Parallel Assignment” |
| Masking | “Quadruple” |

Source: [ClinicalTrials.gov NCT05813275](https://clinicaltrials.gov/study/NCT05813275)

<a id="topic-3.1.1.3-3"></a>

#### Visit schedule and polysomnography timing

> “Participants received AD109 or placebo during a 26-week period, including a 1-week run-in dose followed by 25 weeks at the target dose, then 2 weeks without dosing, followed by last visit at week 28 (Figure S1).”
> “Standard overnight polysomnography (PSG) was performed at baseline and weeks 4 and 26.”
> “Key patient-reported outcomes (PROs) were assessed using PROMIS-Fatigue and PROMIS-Sleep Impairment 8-item questionnaires at baseline and weeks 4, 13, and 26 (Supplementary Methods).”

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

<a id="topic-3.1.1.3-4"></a>

#### Severity strata enrollment limits

> “To ensure representative distribution of baseline AHI4 severity, the size of AHI4 strata will be controlled through enrollment limits, with AHI4 <15 representing ∼20–40% of participants, AHI4 15–30 representing ∼20–40% of participants, and AHI4 >30 representing ∼20–40% of participants.”

Source: [Taranto-Montemurro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12490522/)

> “Our trials were designed to potentially support a broader label indicated for patients across the range of OSA severities by ensuring no more than 40% of the overall study population in each trial could represent mild, moderate or severe patient subgroups.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-3.1.1.3-5"></a>

#### Blinding, central polysomnography scoring, and data monitoring

> “All study participants, investigators, site staff, staff at the PSG scoring center, staff at the CRO and sponsor staff are blinded to treatment assignment throughout the studies.”
> “The studies are conducted with the support of a PSG scoring center (Sleep Strategies, Ottawa, ON) responsible for centralized PSG scoring blinded to treatment assignment for both screening and outcome assessment and generation of standardized PSG variables.”
> “Each participant's baseline and on-treatment PSGs were evaluated by the same scorer to maintain consistency.”
> “An independent DMC, with expertise in sleep apnea, clinical trials, and biostatistics meets regularly to assess unblinded safety data and make recommendations for both trials.”

Source: [Taranto-Montemurro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12490522/)

<a id="topic-3.1.1.3-6"></a>

#### Separate sites from the LunAIRo trial

> “LunAIRo and SynAIRgy were performed in different centers, with the exception of a small number of sites that enrolled for SynAIRgy after the enrollment of LunAIRo was closed. No participant was enrolled in both studies.”

Source: [Taranto-Montemurro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12490522/)

<a id="topic-3.1.1.3-7"></a>

#### Exploratory cohort of GLP-1 receptor agonist users not analyzed

> “An additional exploratory cohort of up to 100 participants receiving a concomitant glucagon-like peptide-1 (GLP-1) receptor agonist specifically for weight loss (ie, not for treatment of type 2 diabetes) was initiated and planned to be analyzed separately to evaluate the potential impact of weight loss on the efficacy and safety of AD109 compared with placebo.”
> “Due to low enrollment in this cohort, the prespecified exploratory analyses are not included in this report.”

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

<a id="topic-3.1.1.3-8"></a>

#### Optional open-label extension after completion

> “Participants completing either of these studies are eligible for an optional open label extension (OLE) study of AD109 in which safety is assessed for up to an additional year (Supplement Information).”

Source: [Taranto-Montemurro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12490522/)

<a id="topic-3.1.1.3-9"></a>

#### Planned randomization and in-treatment polysomnography in the design abstract

> “Approximately 640 participants will be randomized in a 1:1 ratio to receive either placebo or AD109.”
> “Participants will have a PSG on treatment at week 4.”

Source: [Strollo et al. (2024)](https://academic.oup.com/sleep/article/47/Supplement_1/A233/7654816)

<a id="heading-3.1.1.4"></a>

### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

#### Inclusion and exclusion criteria in the publication

> “Patients aged ≥18 years with mild-to-severe OSA who had failed or refused PAP therapy were screened for eligibility.”
> “Participants with AHI ≥5 events/hour were initially enrolled.”
> “An apnea was defined by an event with ≥90% reduction in airflow for ≥10 seconds and hypopnea by ≥30% reduction in airflow for ≥10 seconds associated with a ≥4% decrease in the oxygen saturation.”
> “The eligibility criterion of enrolling participants with AHI ≥5 events/hour was subsequently changed to ≥10 to ≤45 events/hour to avoid overrepresentation of participants with very severe or very mild OSA.”
> “Other inclusion criteria were an 8-item Patient-Reported Outcomes Measurement Information System (PROMIS)–Fatigue T-score >50, representing above-average fatigue and a body mass index (BMI) of 18.5 to 40 kg/m2 in men or 18.5 to 42 kg/m2 in women.”
> “Key exclusion criteria were clinically significant or medically uncontrolled cardiovascular disease, presence of narcolepsy, restless leg syndrome requiring medication, rapid eye movement (REM) sleep behavior disorder, bothersome symptoms of insomnia, and craniofacial malformation syndromes.”

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

<a id="topic-3.1.1.4-2"></a>

#### Registry inclusion criteria, current version

> “PSG criteria: AHI of ≥10 and ≤45; ≤ 25% central or mixed apneas; and PLM arousal index ≤15”
> “PROMIS-Fatigue: raw score ≥17”
> “PAP intolerance or current PAP refusal.”
> “BMI between 18.5 and 40 kg/m2 for men, or 42 kg/m2 for women, inclusive.”

Source: [ClinicalTrials.gov NCT05813275](https://clinicaltrials.gov/study/NCT05813275)

<a id="topic-3.1.1.4-3"></a>

#### Apnea-hypopnea index eligibility range in protocol amendment 5.0, February 2024

> “Version 5.0 February 29, 2024”
> “AHI4 (Hypopneas defined by 4% oxygen desaturation) of ≥10 and ≤45”

Source: [Apnimed SynAIRgy protocol (2025)](https://cdn.clinicaltrials.gov/large-docs/75/NCT05813275/Prot_000.pdf)

<a id="topic-3.1.1.4-4"></a>

#### Registry exclusion criteria

> “Insomnia disorder characterized by difficulty initiating or maintaining sleep, or use within the past month of sedative-hypnotics or other medication for the purpose of treating or avoiding insomnia symptoms.”
> “Clinically significant cardiac disease, e.g., ventricular arrhythmia, untreated or unstable coronary artery disease, cardiac failure.”

Source: [ClinicalTrials.gov NCT05813275](https://clinicaltrials.gov/study/NCT05813275)

<a id="topic-3.1.1.4-5"></a>

#### Definitions of PAP failure and PAP refusal

> “PAP failure is defined as no PAP use for ≥3 months prior to randomization, or return/removal of PAP device from the home.”
> “PAP refusal is defined as refusal of PAP after prior positive sleep study, or prior refusal of provider-recommended sleep study due to unwillingness to consider PAP.”

Source: [Taranto-Montemurro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12490522/)

<a id="topic-3.1.1.4-6"></a>

#### PROMIS-Fatigue threshold expressed as raw score and T-score

> “A PROMIS-Fatigue raw score of 17 is equivalent to a T-score of 50.4.”

Source: [Taranto-Montemurro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12490522/)

<a id="topic-3.1.1.4-7"></a>

#### Additional exclusion criteria in the design paper

> “Clinically significant or medically uncontrolled cardiovascular disease, or resting heart rate >100), untreated or unstable coronary artery disease, heart failure, cerebrovascular event or revascularization within 3 months.”
> “Schizophrenia, schizoaffective disorder, generalized anxiety disorder or bipolar disorder according to DSM-5 criteria”
> “Attempted suicide within 1 year prior to screening, or current suicidal ideation.”
> “Current bothersome symptoms of bladder outlet obstruction including difficulty initiating or maintaining urinary flow, straining, or sensation of incomplete bladder emptying”
> “Blood pressure >145/90 mmHg”
> “Narrow angle glaucoma”
> “Women who are pregnant or nursing”

Source: [Taranto-Montemurro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12490522/)

<a id="topic-3.1.1.4-8"></a>

#### Disallowed concomitant medications

> “Atomoxetine is metabolized by CYP2D6 and aroxybutynin by CYP3A4, and consequently, strong pharmacologic inhibitors of these metabolic enzymes are not allowed as concomitant therapy.”
> “Strong CYP2D6 inhibitors, and strong CYP3A4 inhibitors”
> “Modafinil, armodafinil, solriamfetol, and pitolisant”
> “Oral anticholinergics, and cholinesterase inhibitors”
> “Drugs used exclusively for weight loss”

Source: [Taranto-Montemurro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12490522/)

<a id="topic-3.1.1.4-9"></a>

#### Apnea-hypopnea index eligibility in protocol versions 2.0 and 4.0, July 2023, superseded in February 2024

> “Version 2.0 July 26, 2023”
> “the V2 PSG must be >5 and ≤45, with ≤ 25% central or mixed apneas”

Source: [Apnimed SynAIRgy protocol (2025)](https://cdn.clinicaltrials.gov/large-docs/75/NCT05813275/Prot_000.pdf)

<a id="topic-3.1.1.4-10"></a>

#### Apnea-hypopnea index eligibility in congress abstracts, April 2024 and May 2025, superseded in May 2026

> “Participants were enrolled over the full range of OSA severity as measured by apnea-hypopnea index with 4% desaturation (AHI4) >5 with no upper limit.”

Source: [Strollo et al. (2025b)](https://academic.oup.com/sleep/article/48/Supplement_1/A339/8134797)

> “Eligible participants include adults with AHI4 (4% desaturation definition for hypopneas) ≥5, and a BMI < 42kg/m2 for women and < 40 kg/m2 for men who either decline or are unable to tolerate continuous positive airway pressure treatment.”

Source: [Strollo et al. (2024)](https://academic.oup.com/sleep/article/47/Supplement_1/A233/7654816)

<a id="heading-3.1.1.5"></a>

### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

#### AD109 regimen with one-week run-in and no dose reduction

> “AD109 dose was aroxybutynin 2.5 mg/atomoxetine 37.5 mg for week 1 and aroxybutynin 2.5 mg/atomoxetine 75 mg for the remaining weeks (dose reductions not permitted).”

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

<a id="topic-3.1.1.5-2"></a>

#### Registry intervention descriptions

| Arm | Quoted record |
| --- | --- |
| AD109 | “Aroxybutynin 2.5 mg/atomoxetine 75 mg tablet, administered orally once daily at bedtime (Weeks 2-26). Week 1 run-in: aroxybutynin 2.5 mg/atomoxetine 37.5 mg tablet.” |
| Placebo | “Matching placebo tablet administered orally once daily at bedtime for 26 weeks, with run-in and target dose matched to active arm packaging” |

Source: [ClinicalTrials.gov NCT05813275](https://clinicaltrials.gov/study/NCT05813275)

<a id="topic-3.1.1.5-3"></a>

#### Dispensing and dosing rules

> “The IMP is dispensed as a blister package of 7 run-in dose tablets and a bottle containing 33 target dose tablets.”
> “Dose reduction is not permitted, and dosing is discontinued if the participant experiences intolerance to the assigned study drug.”
> “Participants are not prohibited from initiating PAP during the trial if deemed by the participant's primary care provider to be in the participant's best medical interest.”

Source: [Taranto-Montemurro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12490522/)

<a id="topic-3.1.1.5-4"></a>

#### Run-in dose in base notation and reason dose reduction was not permitted

> “A lower dose of AD109 (2.3/37.5mg) was administered during the one-week run-in period; however, dose reduction was not permitted in the Phase 3 trials, to maximize evaluation of efficacy.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-3.1.1.5-5"></a>

#### Adherence calculation

> “The medication adherence (percent compliant) was calculated as medication adherence = 100 × (total number of doses received/total number of doses expected).”

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

<a id="heading-3.1.1.6"></a>

### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

#### 3.1.1.6.1 Rationale for Using Apnea-Hypopnea Index as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

##### Primary endpoint: change in AHI with 4% desaturation hypopnea rule at week 26

> “The primary efficacy endpoint was the change in AHI from baseline to week 26.”

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

> “AHI, Apnea-Hypopnea Index, is the number of apneas or hypopneas recorded via polysomnography during the study per hour of sleep. Apnea is defined as a cessation of airflow lasting at least 10 seconds, hypopnea as a decrease in airflow by at least 30% from baseline for at least 10 seconds occurring with a drop in oxygen saturation (SpO2) by at least 4%.”

Source: [ClinicalTrials.gov NCT05813275](https://clinicaltrials.gov/study/NCT05813275)

> “Change from baseline to week 26 in AHI4”
> “AHI4 = apnea-hypopnea index based on 4% hypopnea desaturation”

Source: [Apnimed SynAIRgy protocol (2025)](https://cdn.clinicaltrials.gov/large-docs/75/NCT05813275/Prot_000.pdf)

<a id="topic-3.1.1.6.1-2"></a>

##### Key secondary and exploratory endpoints

> “The key secondary efficacy endpoints (at week 26) were change from baseline in oxygen desaturation index based on 3% desaturation (ODI), PROMIS-Fatigue T-score, hypoxic burden based on 4% desaturation (HB), PROMIS-Sleep Impairment T-score, and proportion of participants with ≥50% reduction in AHI.”
> “Prespecified exploratory endpoints (at week 26) included change from baseline in OSA severity category (none [AHI <5], mild [AHI 5 to <15], moderate [AHI 15 to <30], and severe [AHI ≥30]), proportion of participants with AHI reduction of ≥30% to ≥90% by 10% increments, and proportion of breaths with snoring.”

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

<a id="topic-3.1.1.6.1-3"></a>

##### Other secondary endpoints in the design paper

> “Other secondary endpoints in both trials include the change from baseline in the PGI-S score for fatigue at Week 26, the patient global impression of change (PGI-C) score for fatigue at Week 26, and the change from baseline in ESS at Week 26.”

Source: [Taranto-Montemurro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12490522/)

<a id="topic-3.1.1.6.1-4"></a>

##### Rationale for AHI, oxygen desaturation index, and hypoxic burden

> “The primary efficacy endpoint in most OSA trials is the AHI which historically has been the principal biomarker for the disease [[22], [23], [24], [25]].”
> “Compared to AHI4, that only considers the frequency of obstructive events (events/hour of sleep), the HB4 also incorporates the length and the depth of the apnea/hypopnea-related chronic intermittent hypoxia during sleep [16].”
> “This metric has demonstrated a stronger correlation with cardiovascular mortality than AHI in recent epidemiological cohort analyses [16].”

Source: [Taranto-Montemurro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12490522/)

<a id="topic-3.1.1.6.1-5"></a>

##### Rationale for PROMIS-Fatigue as a key secondary endpoint

> “Fatigue is one of the most common and most bothersome symptoms of OSA and is a distinct symptom from sleepiness [13].”
> “PROMIS-Fatigue may provide increased sensitivity to symptom improvement in OSA [31], particularly in the substantial proportion of OSA patients without EDS [32].”

Source: [Taranto-Montemurro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12490522/)

<a id="topic-3.1.1.6.1-6"></a>

##### Content validity and meaningful change of the patient-reported outcome measures, SynAIRgy exit interviews

> “Qualitative exit interviews were conducted with 32 participants within 10 days of completing the trial.”
> “Mapping demonstrated all PROMs have strong concept coverage.”
> “Most participants reported a one-point change on response options for individual items from the PROMIS-Fatigue (61%-96%), PROMIS-Sleep Impairment (52%-96%), and ESS (62-96%) was clinically meaningful, regardless of baseline response.”
> “A one-point change on PROMs represents a clinically meaningful improvement from the patient's perspective.”

Source: [Ojile et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42247851/)

<a id="topic-3.1.1.6.1-7"></a>

##### Investigators' rationale for the clinical meaningfulness of the AHI change, treatment policy and on-treatment estimands

> “At the group level, treatment was associated with a shift in disease severity from the moderate to mild range (from a median of 19.8 at baseline to 13.3 at week 26 in the ITT, and from a median of 19.3 at baseline to 10.6 at week 26 in the on-treatment estimand).”
> “This magnitude of improvement, we believe, is clinically meaningful, as mild OSA has been associated with lower cardiovascular, metabolic, and neurocognitive risk compared to moderate OSA.”
> “At 26 weeks, >25% of participants in the AD109 arm achieved ≥50% reduction in AHI, a clinically meaningful improvement based on American Academy of Sleep Medicine guidelines,45,46 although this effect was not statistically significant compared with the placebo arm.”

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

<a id="topic-3.1.1.6.1-8"></a>

##### Company position on relative rather than absolute AHI change in mild and moderate disease

> “In populations with mild and moderate OSA, meaningful clinical benefits are better reflected by relative reductions in AHI and HB, responder analyses, and shifts to lower disease severity categories, rather than by absolute reductions alone.”
> “Therefore, we believe that assessment of the clinical meaningfulness of response to treatment requires consideration of multiple objective and subjective measures.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-3.1.1.6.1-9"></a>

##### FDA pre-NDA feedback on the clinical meaningfulness of the primary endpoint results

> “In connection with the FDA’s review of our top-line Phase 3 data, at the pre-NDA meeting, the FDA provided feedback about the clinical meaningfulness of certain endpoint results, including the primary endpoint and the limitations of the patient-reported outcomes (PROs).”
> “The FDA indicated that additional analyses and justification may be needed to support that the data demonstrates a clinically meaningful benefit for the treatment of OSA.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-3.1.1.6.1-10"></a>

##### Editorial comment on the clinical significance of the absolute AHI change, treatment policy estimand

> “Among 646 participants (median apnea-hypopnea index [AHI], 19.6), treatment with AD109 over 26 weeks resulted in a placebo-adjusted reduction in AHI of approximately 4 events per hour.”
> “The clinical significance of this magnitude of reduction is uncertain when considered as a continuous measure.”
> “Although such threshold-based outcomes have recognized limitations, these findings suggest that a subset of patients derives a physiologically meaningful benefit.”

Source: [Mehra and Mokhlesi (2026)](https://academic.oup.com/ajrccm/article/212/7/1427/8679096)

<a id="topic-3.1.1.6.1-11"></a>

##### Protocol amendment 6.0 reordering the primary and key secondary endpoints, April 2025

> “Protocol Version: 6.0”
> “17 April 2025”
> “The order of endpoints, including the primary endpoint and key secondary endpoints, was changed to align with recent regulatory approvals for the treatment of OSA related to obesity.”

Source: [Apnimed SynAIRgy protocol (2025)](https://cdn.clinicaltrials.gov/large-docs/75/NCT05813275/Prot_000.pdf)

<a id="topic-3.1.1.6.1-12"></a>

##### Primary endpoint: responder proportion in protocol version 4.0, December 2023, superseded in April 2025

> “Version 4.0 December 15, 2023”
> “The sample size for the primary cohort has been selected based on the number of participants required to provide at least 90% power for the primary endpoint (proportion of participants with a ≥ 50% reduction from baseline to week 26 in AHI) and the first key secondary endpoint (change from baseline to week 26 in PROMIS Fatigue T-score).”
> “The primary clinical question of interest for the primary endpoint is: what is the difference”
> “between AD109 and placebo in the AHI response rate at Week 26”

Source: [Apnimed SynAIRgy protocol (2025)](https://cdn.clinicaltrials.gov/large-docs/75/NCT05813275/Prot_000.pdf)

<a id="topic-3.1.1.6.1-13"></a>

##### Primary endpoint: responder proportion in the registry record, March 2025, superseded in November 2025

> “Viewing V22 (2025-03-18)”
> “23 2025-11-18 Study Status Outcome Measures”
> “Efficacy of AD109 on airway obstruction in mild to sever OSA”
> “Proportion of participants with reduction in AHI (AHI, average number of events for every hour of sleep), measured by polysomnography”

Source: [ClinicalTrials.gov NCT05813275 version 22](https://clinicaltrials.gov/study/NCT05813275?tab=history&a=22)

<a id="topic-3.1.1.6.1-14"></a>

##### Primary endpoint: responder proportion in congress abstracts, April 2024 and May 2025, superseded in May 2025

> “The primary endpoint is the response rate in the AD109 arm vs. placebo arm, where response is defined as >50% reduction in AHI4 from baseline to 26-week polysomnogram (PSG).”

Source: [Strollo et al. (2024)](https://academic.oup.com/sleep/article/47/Supplement_1/A233/7654816)

> “The primary efficacy endpoint is the proportion of participants with ≥50% reduction in AHI4 at six months.”

Source: [Strollo et al. (2025b)](https://academic.oup.com/sleep/article/48/Supplement_1/A339/8134797)

<a id="heading-3.1.1.7"></a>

### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

#### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

##### Planned sample size and power

> “The sample size (640 participants) was calculated based on the number of participants required to provide >90% power for the primary endpoint and one of the key secondary efficacy endpoints (change from baseline to week 26 in PROMIS-Fatigue T-score) at a 2-sided significance level of 0.05 (Supplementary Methods).”

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

<a id="topic-3.1.1.7.1-2"></a>

##### Sample size assumptions from the MARIPOSA trial

> “In a previous Phase 2 study (MARIPOSA), the standard deviation of the placebo group change from baseline in AHI4 was approximately 9.0.”
> “Based on the observed dropout rates in MARIPOSA, it is assumed that the dropout rate in the placebo group will be 5% and the dropout rate in the AD109 group will be 25%.”
> “A total of 640 participants (320/group) will provide >98% power to detect a treatment difference of ≥ 4 points between AD109 and placebo for the change in AHI4.”
> “With these assumptions, simulation demonstrated that 640 participants (320/group) would provide approximately 90% power to detect a treatment difference of 2.5 points and approximately 95% power to detect a treatment difference of 2.75 points.”

Source: [Taranto-Montemurro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12490522/)

<a id="topic-3.1.1.7.1-3"></a>

##### Participants randomized and analyzed

| Population | AD109 | Placebo | Total |
| --- | --- | --- | --- |
| Randomized, all cohorts | “AD109 (n = 324)” | “placebo (n = 322)” | “646 participants” |
| Randomized, main cohort | “AD109 (n = 319)” | “placebo (n = 320)” | “639 participants” |
| Intent-to-treat set (treatment policy estimand) | “AD109 (n = 302)” | “Placebo (n = 313)” | “ITT (N = 615)” |
| On-treatment estimand | “AD109 (n = 260)” | “Placebo (n = 296)” | “On-treatment estimand (N = 556)” |
| Safety analysis set | “AD109a (n = 325)” | “Placebo (n = 319)” | “Safety analysis set (N = 644)” |

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

<a id="topic-3.1.1.7.1-4"></a>

##### Participants excluded from the efficacy analyses

> “The 7 participants (5 in the AD109 arm and 2 in the placebo arm) randomized and treated in the exploratory cohort are included in the safety analysis but not in the efficacy analyses.”
> “Sixteen participants enrolled at site 1416 in the AD106 arm were excluded from the efficacy analyses because the site was terminated due to Good Clinical Practice noncompliance.”
> “Six participants enrolled at site 1416 in the placebo arm were excluded from the efficacy analyses because the site was terminated due to Good Clinical Practice noncompliance.”
> “These numbers reflect participants by assigned treatment, but 2 participants who were assigned to placebo received AD109 instead.”

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

<a id="heading-3.1.1.7.2"></a>

#### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

##### Treatment policy estimand (intent-to-treat) and on-treatment estimand

> “Primary analyses of the efficacy endpoints were performed using an intent-to-treat approach (ITT); supportive analyses were performed using the on-treatment estimand.”
> “The ITT analysis included all randomized participants who received ≥1 dose of AD109/placebo and evaluated endpoints regardless of treatment adherence or discontinuation.”
> “For the ITT estimand, missing data were assumed to be missing-not-at-random, and endpoints were analyzed with a pattern-mixture model using a jump-to-reference approach by means of sequential modeling with multiple imputation.”
> “The on-treatment estimand included all randomized participants who received ≥1 dose of AD109/placebo and who had ≥1 post-baseline PSG assessment on treatment.”
> “The on-treatment estimand focused on endpoints observed during active treatment exposure and excluded data collected after treatment discontinuation, with missing values imputed using a last observation carried forward approach.”

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

<a id="topic-3.1.1.7.2-2"></a>

##### Registry definitions of the Primary Full Analysis Set and While-on-Treatment population

> “The Primary Full Analysis Set includes all participants who were not from the terminated site 1416, who were randomized into the main cohort and received at least 1 dose of IMP.”

Source: [ClinicalTrials.gov NCT05813275 results](https://clinicaltrials.gov/study/NCT05813275?tab=results)

<a id="topic-3.1.1.7.2-3"></a>

##### Statistical model and responder analysis

> “The primary analysis for the primary and secondary endpoints defined on a continuous scale used a restricted maximum likelihood–based mixed model for repeated measurements in combination with the Newton–Raphson algorithm.”
> “Analysis of the proportion of participants with ≥50% reduction in AHI at week 26 (key secondary endpoint not on a continuous scale) was conducted using the stratified Cochran–Mantel–Haenszel procedure, and estimates of risk difference between arms, along with the 2-sided 95% CI, were calculated based on the Cochran–Mantel–Haenszel stratum weights38 and the Sato variance estimator.39”
> “For the proportion of participants with ≥50% reduction in AHI, participants who discontinued treatment were considered nonresponders.”

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

<a id="topic-3.1.1.7.2-4"></a>

##### Multiplicity control and hierarchical testing order

> “For the primary endpoint, no adjustment for multiplicity was needed and a 2-sided 5% significance level was used.”
> “Adjustment for multiplicity of the key secondary endpoints was conducted through a closed testing approach, where each key secondary endpoint was tested in a prespecified order: (1) change from baseline to week 26 in ODI, (2) change from baseline to week 26 in PROMIS-Fatigue T-score, (3) change from baseline to week 26 in HB, (4) change from baseline to week 26 in PROMIS-Sleep Impairment T-score, and (5) proportion of participants with ≥50% reduction in AHI at week 26.”
> “Key secondary endpoints that are nominally statistically significant but occur after a nonsignificant result in the prespecified hierarchical testing sequence should be interpreted with caution, as formal statistical significance cannot be claimed.”

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

<a id="topic-3.1.1.7.2-5"></a>

##### Relative change in AHI on the log scale added as an exploratory analysis in statistical analysis plan version 2.0, April 2025

> “SAP Text Version Number: 2.0”
> “SAP Text Date: 22-Apr-2025”
> “Protocol Version and Date: V6.0, 17-Apr-2025”
> “Added an exploratory analysis of AHI4 to assess the relative change on the log scale in section 8.1”

Source: [Apnimed SynAIRgy statistical analysis plan (2025)](https://cdn.clinicaltrials.gov/large-docs/75/NCT05813275/SAP_001.pdf)

<a id="topic-3.1.1.7.2-6"></a>

##### Safety analysis set

> “Safety was evaluated in the safety analysis set, including all randomized participants who received ≥1 dose of AD109/placebo (Supplementary Methods).”

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

<a id="topic-3.1.1.7.2-7"></a>

##### Per-protocol population as described by the company

> “In addition, supportive per-protocol analyses were performed in a prespecified per-protocol population, defined prior to database lock and unblinding, consisting of participants who were adherent to treatment (≥70% compliance) and had no major protocol deviations, providing additional context on clinical response to treatment under conditions of consistent use.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="heading-3.1.1.8"></a>

### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

#### 3.1.1.8.1 Participant Disposition

<a id="topic-3.1.1.8.1-1"></a>

##### Trial completion and completion of six months of treatment

> “Among participants who received treatment, 84.6% (539/637) completed the trial, with 83.3% (265/318) in the AD109 group and 85.9% (274/319) in the placebo group.”
> “Overall, 74.7% (476/637) completed 6 months of treatment (65.7% [209/318] with AD109 and 83.7% [267/319] with placebo; Figure 1).”

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

<a id="topic-3.1.1.8.1-2"></a>

##### Treatment adherence

> “In the AD109 arm, treatment adherence (percent compliant) was 95.7% (SD, 9.2%) for participants completing the study on treatment, and 90.2% (SD, 35.2%) for those discontinuing treatment.”
> “In the placebo arm, treatment adherence was 95.5% (SD, 9.5%) for participants completing the study on treatment, and 77.5% (SD, 42.4%) for those discontinuing treatment.”

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

<a id="topic-3.1.1.8.1-3"></a>

##### Overall treatment discontinuation before week 26

> “Limitations of this trial include that the substantial drug discontinuation rate before 26 weeks (34.3% for AD109 vs 16.3% for placebo) likely diminished the magnitude of benefits observed.”

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

> “In SynAIRgy, among participants randomized in the main cohort, AEs led to treatment discontinuation prior to month 6 in 21.2% of participants receiving AD109 compared with 3.1% on placebo, contributing to overall discontinuation rates of 34.6% for AD109 and 16.5% for placebo at month 6.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-3.1.1.8.1-4"></a>

##### Timing of treatment discontinuation

> “AE-related discontinuations occurred predominantly early after treatment initiation, with markedly fewer events later in the treatment period (Figure S10).”
> “In contrast, non-AE-related discontinuations were similar between the AD109 and placebo arms and were distributed more uniformly over time and generally at lower counts.”

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

<a id="topic-3.1.1.8.1-5"></a>

##### Registry participant flow and reasons for study withdrawal

| Milestone or reason | AD109 | Placebo |
| --- | --- | --- |
| Started | “324” | “322” |
| Completed | “269” | “276” |
| Not completed | “55” | “46” |
| Adverse event | “4” | “1” |
| Lost to follow-up | “15” | “15” |
| Physician decision | “2” | “2” |
| Site terminated by sponsor | “8” | “2” |
| Withdrawal by subject | “21” | “22” |
| Other or not reported | “5” | “4” |

Source: [ClinicalTrials.gov NCT05813275 results](https://clinicaltrials.gov/study/NCT05813275?tab=results)

<a id="topic-3.1.1.8.1-6"></a>

##### Main cohort completion in the congress abstract

> “Eligible participants (N=639) were randomized (AD109: n=319; PBO: n=320) with 539 (84.6%) completing the trial.”

Source: [Strollo et al. (2025c)](https://journal.chestnet.org/article/S0012-3692%2825%2905441-8/fulltext)

<a id="heading-3.1.1.8.2"></a>

#### 3.1.1.8.2 Baseline Characteristics

<a id="topic-3.1.1.8.2-1"></a>

##### Baseline characteristics, intent-to-treat set, AHI with 4% desaturation hypopnea rule

| Characteristic | AD109 | Placebo | Total |
| --- | --- | --- | --- |
| Participants | “AD109 (n = 302)” | “Placebo (n = 313)” | “Total (N = 615)” |
| Age, years, median (minimum-maximum) | “59 (24-83)” | “58 (25-87)” | “58 (24-87)” |
| Female, n (%) | “150 (49.7)” | “153 (48.9)” | “303 (49.3)” |
| Black or African American, n (%) | “55 (18.2)” | “62 (19.8)” | “117 (19.0)” |
| White, n (%) | “212 (70.2)” | “216 (69.0)” | “428 (69.6)” |
| Asian, n (%) | “23 (7.6)” | “22 (7.0)” | “45 (7.3)” |
| Hispanic or Latino, n (%) | “63 (20.9)” | “69 (22.0)” | “132 (21.5)” |
| Body weight, kg, mean (SD) | “93.3 (17.0)” | “93.1 (17.1)” | “93.2 (17.0)” |
| BMI, kg/m2, median (minimum-maximum) | “32.5 (18.5-41.9)” | “32.4 (20.1-42.0)” | “32.4 (18.5-42.0)” |
| BMI 18.5-29.9 kg/m2, n (%) | “107 (35.4)” | “102 (32.6)” | “209 (34.0)” |
| BMI 30-34.9 kg/m2, n (%) | “100 (33.1)” | “111 (35.5)” | “211 (34.3)” |
| BMI 35 kg/m2 or higher, n (%) | “95 (31.5)” | “100 (31.9)” | “195 (31.7)” |
| AHI, events/h, median (minimum-maximum) | “19.8 (5.2-101.8)” | “19.1 (5.1-70.0)” | “19.6 (5.1-101.8)” |
| Mild OSA, AHI 5 to <15, n (%) | “105 (34.8)” | “109 (34.8)” | “214 (34.8)” |
| Moderate OSA, AHI 15 to <30, n (%) | “125 (41.4)” | “134 (42.8)” | “259 (42.1)” |
| Severe OSA, AHI 30 or higher, n (%) | “72 (23.8)” | “70 (22.4)” | “142 (23.1)” |
| ODI, events/h, median (minimum-maximum) | “27.3 (6.8-96.3)” | “26.9 (4.5-79.3)” | “27.0 (4.5-96.3)” |
| HB, %min/h, median (minimum-maximum) | “33.7 (0.8-379.8)” | “28.8 (2.4-272.8)” | “31.1 (0.8-379.8)” |
| PROMIS-Fatigue T-score, mean (SD) | “59.2 (7.0)” | “58.9 (6.7)” | “59.0 (6.8)” |
| PROMIS-Sleep Impairment T-score, mean (SD) [n] | “58.9 (7.2) [299]” | “58.6 (7.4) [309]” | “58.7 (7.3) [608]” |
| ESS score, mean (SD) [n] | “10.0 (4.6) [299]” | “10.1 (4.7) [311]” | “10.0 (4.6) [610]” |
| PAP intolerance, n (%) | “208 (68.9)” | “203 (64.9)” | “411 (66.8)” |
| PAP refusal, n (%) | “94 (31.1)” | “111 (35.5)” | “205 (33.3)” |
| Hypertension, n (%) | “152 (50.3)” | “153 (48.9)” | “305 (49.6)” |
| Diabetes, n (%) | “52 (17.2)” | “51 (16.3)” | “103 (16.7)” |
| Mood disturbances, n (%) | “60 (19.9)” | “45 (14.4)” | “105 (17.1)” |
| Insomnia, n (%) | “17 (5.6)” | “15 (4.8)” | “32 (5.2)” |

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

<a id="topic-3.1.1.8.2-2"></a>

##### Distribution of baseline severity and body mass index in the intent-to-treat set

> “The distribution of baseline OSA severity was broad and right-skewed with 34.8% (214/615) mild, 42.1% (259/615) moderate, and 23.1% (142/615) severe (Table 1, Figure S2).”
> “Baseline insomnia was assessed based on participant-reported medical history obtained at screening and includes initial insomnia (difficulty falling asleep at the beginning of the night), insomnia, and middle insomnia (difficulty maintaining sleep, characterized by frequent or prolonged nighttime awakenings).”

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

<a id="topic-3.1.1.8.2-3"></a>

##### Registry baseline age and mean AHI with 4% desaturation hypopnea rule, Primary Full Analysis Set

| Characteristic | AD109 | Placebo | Total |
| --- | --- | --- | --- |
| Age, years, mean (SD) | “57.5(10.67)” | “57.1(11.11)” | “57.3(10.89)” |
| Baseline AHI4, events/hr, mean (SD) | “22.13(11.819)” | “21.47(10.607)” | “21.79(11.214)” |

Source: [ClinicalTrials.gov NCT05813275 results](https://clinicaltrials.gov/study/NCT05813275?tab=results)

<a id="topic-3.1.1.8.2-4"></a>

##### Baseline characteristics, all 646 randomized participants, AHI with 4% desaturation hypopnea rule

> “At baseline, the mean (SD) age was 57.1 (11.0) years, and mean (SD) BMI was 32.3 (5.0) kg/m2 with a balanced proportion of female (n=317, 49.1%) and male (329, 50.9 %) participants.”
> “The mean (SD) AHI4 at baseline was 22 (11) with 34.4%, 42.4%, and 23.2% of participants having mild (AHI4 5–< 15) moderate (AHI4 15–< 30), or severe (AHI4 ≥30) OSA, respectively.”
> “Mean (SD) PROMIS-Fatigue T-score was 59.1 (7.0), mean (SD) PROMIS-Sleep Impairment T-score score was 58.5 (7.5), and mean (SD) ESS was 10.1 (4.7).”

Source: [Strollo et al. (2025b)](https://academic.oup.com/sleep/article/48/Supplement_1/A339/8134797)

<a id="topic-3.1.1.8.2-5"></a>

##### Baseline oxygenation measures, all 646 randomized participants

| Characteristic | Quoted value |
| --- | --- |
| ODI3, mean (SD) | “29 (13)” |
| HB4, mean (SD) | “43 (40)” |

Source: [Taranto-Montemurro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12490522/)

<a id="heading-3.1.1.8.3"></a>

#### 3.1.1.8.3 Efficacy Results

<a id="topic-3.1.1.8.3-1"></a>

##### Primary and key secondary endpoints at week 26, treatment policy estimand, AHI with 4% desaturation hypopnea rule

| Endpoint | AD109 | Placebo | Difference | 95% CI | P value |
| --- | --- | --- | --- | --- | --- |
| Change in AHI, LS mean (95% CI), events/h (primary) | “−3.3 (−5.1 to −1.5)” | “0.7 (−1.0 to 2.4)” | “−4.0” | “(−6.4 to −1.6)” | “P = .001” |
| Change in ODI, LS mean (95% CI), events/h | “−3.7 (−5.6 to −1.7)” | “0.9 (−1.1 to 2.8)” | “−4.5” | “(−7.3 to −1.8)” | “P = .001” |
| Change in PROMIS-Fatigue T-score, LS mean (95% CI) | “−7.4 (−8.3 to −6.5)” | “−6.2 (−7.1 to −5.3)” | “−1.2” | “(−2.4 to 0.0)” | “P = .059” |
| Percent reduction in geometric mean HB, LS mean (95% CI) | “44.7 (34.5-53.4)” | “8.5 (‒8.1 to 22.5)” | “39.6” | “(23.6-52.3)” | “P <.0001” |
| Change in PROMIS-Sleep Impairment T-score, LS mean (95% CI) | “−7.6 (−8.5 to −6.6)” | “−6.9 (−7.8 to −5.9)” | “−0.7” | “(−2.0 to 0.7)” | “P = .316” |
| Participants with ≥50% reduction in AHI, n (%) | “78 (25.8)” | “62 (19.8)” | “5.7” | “(−1.0 to 12.4)” | “P = .182” |

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

<a id="topic-3.1.1.8.3-2"></a>

##### Relative reduction in AHI with 4% desaturation hypopnea rule at week 26, treatment policy estimand

> “These changes represent a model-estimated 44.1% geometric mean reduction in AHI from baseline to week 26 in the AD109 arm vs 17.6% reduction in the placebo arm (P <.0001; Figure 2A).”
> “The median (95% CI) AHI was reduced from 19.8 (18.3-21.2) in the moderate severity range at baseline to 13.3 (10.7-15.9) in the mild severity range at week 26 with AD109, and from 19.1 (17.0-20.2) at baseline to 17.7 (15.3-20.8) at week 26 with placebo (Figure 2B; Table S1).”

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

<a id="topic-3.1.1.8.3-3"></a>

##### Week 4 placebo-adjusted AHI change and responder difference, treatment policy estimand

> “The placebo-adjusted reduction at week 4 was −5.7 (−7.5 to −3.8); P <.0001.”
> “The treatment difference at week 4 was 21.7 (14.8-28.5); P <.0001.”

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

<a id="topic-3.1.1.8.3-4"></a>

##### Registry primary endpoint result for change in AHI with 4% desaturation hypopnea rule at 6 months, treatment policy and while-on-treatment estimands

| Analysis | AD109, LS mean | Placebo, LS mean | LS mean difference | 95% CI lower limit | 95% CI upper limit | P value |
| --- | --- | --- | --- | --- | --- | --- |
| “Primary Full Analysis Set (Treatment Policy Estimand)” | “-3.28” | “0.71” | “-3.99” | “-6.40” | “-1.59” | “0.001” |
| “While-on-Treatment population” | “-6.11” | “0.44” | “-6.54” | “-8.80” | “-4.28” | “<0.0001” |

Source: [ClinicalTrials.gov NCT05813275 API record](https://clinicaltrials.gov/api/v2/studies/NCT05813275)

> “The While-on-Treatment population is the MITT set, which includes participants in the PFAS who had at least one post-baseline on-treatment polysomnography (PSG) assessment.”
> “Analyses were conducted under the While-on-Treatment Estimand”

Source: [ClinicalTrials.gov NCT05813275 API record](https://clinicaltrials.gov/api/v2/studies/NCT05813275)

<a id="topic-3.1.1.8.3-5"></a>

##### Primary and key secondary endpoints at week 26, on-treatment estimand, AHI with 4% desaturation hypopnea rule

| Endpoint | AD109 | Placebo | Difference | 95% CI | P value |
| --- | --- | --- | --- | --- | --- |
| Change in AHI, LS mean (95% CI), events/h (primary) | “−6.1 (−7.8 to −4.4)” | “0.4 (−1.2 to 2.0)” | “−6.5” | “(−8.8 to −4.3)” | “P <.0001” |
| Change in ODI, LS mean (95% CI), events/h | “−6.5 (−8.4 to −4.6)” | “0.7 (−1.1 to 2.5)” | “−7.2” | “(−9.8 to −4.7)” | “P <.0001” |
| Change in PROMIS-Fatigue T-score, LS mean (95% CI) | “−7.5 (−8.4 to −6.6)” | “−6.2 (−7.0 to −5.3)” | “−1.4” | “(−2.6 to −0.1)” | “P = .030” |
| Percent reduction in geometric mean HB, LS mean (95% CI) | “60.5 (52.8-66.9)” | “14.7 (‒0.7 to 27.8)” | “53.6” | “(41.0-63.6)” | “P <.0001” |
| Change in PROMIS-Sleep Impairment T-score, LS mean (95% CI) | “−7.6 (−8.6 to −6.7)” | “−6.8 (−7.7 to −5.9)” | “−0.8” | “(−2.2 to 0.5)” | “P = .231” |
| Participants with ≥50% reduction in AHI, n (%) | “103 (39.6)” | “66 (22.3)” | “17.3” | “(9.6-25.0)” | “P <.0001” |

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

<a id="topic-3.1.1.8.3-6"></a>

##### Relative and median AHI with 4% desaturation hypopnea rule at week 26, on-treatment estimand

> “In the mITT (AD109: n=260; PBO: n=296), the AHI4 (events/hr) was reduced from a median (IQR) of 19.3 (12.7–28.7) at baseline to 10.6 (5.3–20.0) at Week 26 with AD109 and from 19.2 (12.9–29.1) at baseline to 18.0 (9.2–30.5) at Week 26 with PBO.”
> “In the mITT, AD109 significantly reduced AHI4 (LS mean [95% CI]) at Week 26 by −6.1 (−7.8, −4.4) vs 0.4 (−1.2, 2.0) with PBO (p<0.0001), representing a 55.6% improvement (vs 19.1% with PBO; p<0.0001).”

Source: [Strollo et al. (2025c)](https://journal.chestnet.org/article/S0012-3692%2825%2905441-8/fulltext)

<a id="topic-3.1.1.8.3-7"></a>

##### Week 4 placebo-adjusted AHI change and responder difference, on-treatment estimand

> “The placebo-adjusted reduction at week 4 was −6.7 (−8.7 to −4.8); P <.0001.”
> “The treatment difference at week 4 was 27.1 (19.7-34.4); P <.0001.”

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

<a id="topic-3.1.1.8.3-8"></a>

##### Relative AHI reduction by estimand as reported by the company

> “SynAIRgy: Treatment Policy Estimand: AD109 significantly reduced AHI by 44.1% vs placebo (17.6%; p<0.0001); On Treatment Estimand: AD109 significantly reduced AHI by 55.6% vs placebo (19.1%; p<0.0001)”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-3.1.1.8.3-9"></a>

##### Topline primary endpoint result and relative AHI reduction, as reported in the company release

> “The SynAIRgy trial met its primary endpoint: mean change from baseline in the apnea-hypopnea index (AHI) at 26 weeks compared to placebo (p=0.001).”
> “Study participants treated with AD109 achieved a mean reduction in AHI of 55.6% from baseline and achieved significantly improved oxygenation and reduced disease severity”

Source: [Apnimed SynAIRgy topline release (2025)](https://apnimed.com/article/ad109phase3toplineresults/)

<a id="topic-3.1.1.8.3-10"></a>

##### Responders with at least 50% AHI reduction at weeks 4 and 26, treatment policy and on-treatment estimands

> “SynAIRgy: Treatment Policy Estimand: AD109 reduced AHI≥50% in 25.8% of participants vs placebo (19.8%; p=0.182); On Treatment Estimand: AD109 significantly reduced AHI ≥50% in 39.6% of participants vs placebo (22.3%; p<0.0001).”
> “For participants achieving an AHI reduction of > 50%, a supportive treatment policy analysis that treated only missing data as non-response demonstrated statistically significant differences favoring AD109 (week 26 p=0.006), supporting the responder findings despite unequal discontinuation rates and a non-trivial placebo response.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

> “Clinically meaningful response was observed as early as week 4 based on the ≥50% reduction in AHI responder rates, suggesting that the lower treatment difference at week 26 could be attributed to the higher early treatment discontinuation rate with AD109 relative to placebo, since participants who discontinued treatment were classified as nonresponders in this analysis.”

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

<a id="topic-3.1.1.8.3-11"></a>

##### Severity category improvement and disease control at week 26, treatment policy estimand

> “AD109 improved OSA disease severity category in 41.8% of participants (vs 33.6% for placebo), with 17.6% achieving complete OSA disease control (AHI <5) at week 26 vs 9.3% for placebo (P = .012; Figure 2C).”
> “Reductions ≥70% in AHI at week 26 were reported in 17.2% (52/302) of the AD109 arm vs 8.9% (28/313) in the placebo arm (P = .003; Figure 3A).”

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

<a id="topic-3.1.1.8.3-12"></a>

##### Severity category improvement and disease control at week 26, on-treatment estimand

> “Results from the SynAIRgy trial as published in AJRCCM (on treatment estimand):”
> “22.3% of participants achieved disease control (AHI <5 events/hour)”

Source: [Apnimed SynAIRgy publication release (2026)](https://ir.apnimed.com/news-releases/news-release-details/apnimed-announces-publication-its-phase-3-synairgy-trial-ad109)

> “In the mITT population, AD109 achieved a significant reduction in mean AHI from baseline (55.6%, p<0.0001) compared to placebo (19.1%, p<0.0001) at 26 weeks.”
> “51.2% of participants treated with AD109 showed a reduction in OSA disease severity category”
> “22.3% of participants treated with AD109 achieved complete OSA disease control (defined as AHI <5 events/hour)”

Source: [Apnimed CHEST 2025 release (2025)](https://apnimed.com/article/apnimed-to-present-additional-phase-3-data-for-ad109-an-investigational-oral-pill-for-obstructive-sleep-apnea-at-chest-2025-annual-meeting/)

<a id="topic-3.1.1.8.3-13"></a>

##### Oxygen desaturation index with 3% desaturation criterion, relative change by estimand

> “SynAIRgy: Treatment Policy Estimand: AD109 significantly reduced ODI3 of 34.3% (3.7 events/hr) vs placebo (10.8%; +0.9 events/hr; p=0.001) at week 26; On Treatment Estimand: AD109 significantly reduced ODI3 of 44.0% (6.5 events/hr) vs placebo (11.2%; +0.7 events/hr; p<0.0001) at week 26.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-3.1.1.8.3-14"></a>

##### Oxygen desaturation index and hypoxic burden, on-treatment estimand, as reported in the CHEST 2025 company release

> “Significant improvements in oxygenation as assessed by mean reductions in HB4 (60.5%, p<0.0001) and ODI3 (44.8%, p<0.0001)”

Source: [Apnimed CHEST 2025 release (2025)](https://apnimed.com/article/apnimed-to-present-additional-phase-3-data-for-ad109-an-investigational-oral-pill-for-obstructive-sleep-apnea-at-chest-2025-annual-meeting/)

<a id="topic-3.1.1.8.3-15"></a>

##### Hypoxic burden with 4% desaturation criterion outside formal hierarchical testing, treatment policy estimand

> “Based on the prespecified hierarchical testing approach for secondary endpoints, formal endpoint testing ended before analysis of HB.”
> “The geometric mean percent reduction in HB at week 26 was 44.7% for participants in the AD109 arm vs 8.5% for participants in the placebo arm (nominal P <.0001; Table 2).”

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

<a id="topic-3.1.1.8.3-16"></a>

##### Non-REM, REM, and supine AHI with 4% desaturation hypopnea rule at week 26, on-treatment estimand

| Measure | AD109 change, LS mean (95% CI) | Placebo change, LS mean (95% CI) | Difference | 95% CI | P value |
| --- | --- | --- | --- | --- | --- |
| Non-REM AHI, events/h | “−3.7 (−5.6 to −1.8)” | “0.8 (−1.0 to 2.6)” | “−4.5” | “(−7.1 to −2.0)” | “P <.001” |
| REM AHI, events/h | “−3.6 (−6.7 to −0.5)” | “−0.2 (−2.7 to 2.3)” | “−3.4” | “(−7.4 to 0.6)” | “P = .092” |
| Supine AHI, events/h | “−7.4 (−10.0 to −4.8)” | “−2.5 (−4.9 to −0.1)” | “−4.9” | “(−8.4 to −1.4)” | “P = .006” |

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

<a id="topic-3.1.1.8.3-17"></a>

##### Apnea index and hypopnea index at week 26, on-treatment estimand

> “At week 26 in SynAIRgy, AD109 was associated with a 77.2% mean reduction from baseline in the apnea index among patients who remained on treatment (vs 20.2% on placebo), compared with a smaller mean relative reduction of approximately 45.3% in the hypopnea index (vs 12.4% on placebo).”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-3.1.1.8.3-18"></a>

##### Arousal indexes at week 26, on-treatment estimand

| Measure | AD109 change, median (IQR) | Placebo change, median (IQR) |
| --- | --- | --- |
| Respiratory arousal index, events/h | “0.1 (−5.0 to 5.8)” | “1.3 (−3.5 to 7.5)” |
| Total arousal index, events/h | “2.9 (−2.5 to 10.5)” | “1.6 (−3.9 to 8.7)” |

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

<a id="topic-3.1.1.8.3-19"></a>

##### Subgroups and adjustment for REM sleep and body mass index, treatment policy and on-treatment estimands

> “Similar improvements in AHI at week 26 were observed among participants in the AD109 arm across various subgroups including sex, baseline OSA severity categories (mild, moderate, and severe), and BMI classes (Figure S3).”
> “AD109 treatment effects on AHI were consistent across estimands, with larger effect sizes observed in the supportive on-treatment estimand in participants who tolerated treatment (Table 3, Figure 2D and E, Figure S3).”
> “The evaluation of the treatment effect on AHI and HB at week 26 performed with an adjusted model including the change from baseline in proportion of REM sleep and BMI is provided in Table S3 and shows that the reduction in AHI is independent from reduction in REM and BMI in the treatment arm.”

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

<a id="topic-3.1.1.8.3-20"></a>

##### Snoring, exploratory endpoint

> “AD109 reduced snoring vs placebo (Table S2).”

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

<a id="heading-3.1.1.8.4"></a>

#### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.1.8.4-1"></a>

##### PROMIS-Fatigue at week 26, treatment policy and on-treatment estimands

> “AD109 reduced PROMIS-Fatigue T-scores at week 26 by a mean of 7.4 points compared with 6.2 points in the control arm, such that the difference between arms did not meet statistical significance (P = .059; Table 2).”
> “In the supportive on-treatment estimand analyses, PROMIS-Fatigue T-scores fell at week 26 by 7.5 points with AD109 vs 6.2 points with placebo (P = .030; Table 3).”

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

<a id="topic-3.1.1.8.4-2"></a>

##### PROMIS-Fatigue by baseline fatigue and daytime sleepiness, treatment policy estimand

> “The impact of AD109 on PROMIS-Fatigue T-score at week 26 was more pronounced in participants who were more fatigued (P = .049) or had more daytime sleepiness (P = .007) at baseline (Figure S6).”

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

<a id="topic-3.1.1.8.4-3"></a>

##### PROMIS-Sleep Impairment at week 26, treatment policy estimand

> “The PROMIS-Sleep Impairment T-score improved by 7.6 points in the AD109 arm but the improvement in the placebo arm was similar, such that no treatment effect was observed between arms (P = .316; Table 2).”

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

<a id="topic-3.1.1.8.4-4"></a>

##### PROMIS-Fatigue and PROMIS-Sleep Impairment at week 26, on-treatment estimand, congress abstract

> “In the mITT, the change from baseline PROMIS-Fatigue and PROMIS-Sleep Impairment T-scores (LS mean [95% CI]) at Week 26 were −7.5 (−8.4, −6.6) and −7.6 (−8.6, −6.7) with AD109 compared to −6.2 (−7.0, −5.3) and −6.8 (−7.7, −5.9) with PBO, respectively (p=0.03; p=0.23).”

Source: [Strollo et al. (2025c)](https://journal.chestnet.org/article/S0012-3692%2825%2905441-8/fulltext)

<a id="topic-3.1.1.8.4-5"></a>

##### Placebo response in patient-reported outcomes

> “The substantial improvement in symptoms observed in both arms suggests that the placebo effect may have impaired the ability to detect true clinical improvements.”
> “In the context of PRO assessments, participants were never specifically asked if they were aware of receiving placebo, so we cannot rule out the possibility of expectation bias influencing responses.”

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

> “In the SynAIRgy clinical trial, although we did not observe a greater improvement in fatigue overall with AD109 which may have been due to a high placebo effect, in participants with more EDS symptoms at baseline, AD109 led to improvements in symptoms of fatigue relative to placebo.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-3.1.1.8.4-6"></a>

##### Editorial comment on patient-reported outcomes

> “Notably, no overall significant improvements were observed in patient-reported outcomes, such as fatigue, in the background of overall minimal baseline symptoms.”
> “However, among participants with greater baseline symptom burden of fatigue and sleepiness, improvements in Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue scores were observed, suggesting that symptomatic benefit may be confined to selected subgroups.”

Source: [Mehra and Mokhlesi (2026)](https://academic.oup.com/ajrccm/article/212/7/1427/8679096)

<a id="topic-3.1.1.8.4-7"></a>

##### Epworth Sleepiness Scale and patient global impression endpoints

No evidence found.

<a id="heading-3.1.1.8.5"></a>

#### 3.1.1.8.5 Safety Results

<a id="topic-3.1.1.8.5-1"></a>

##### Overall safety summary, safety analysis set

| Event | AD109 (n = 325), n (%) | Placebo (n = 319), n (%) |
| --- | --- | --- |
| Any TEAE | “230 (70.8)” | “149 (46.7)” |
| Any treatment-related TEAE | “190 (58.5)” | “75 (23.5)” |
| Any severe TEAE | “15 (4.6)” | “10 (3.1)” |
| Any serious TEAE | “5 (1.5)” | “8 (2.5)” |
| Any TEAE leading to treatment discontinuation | “69 (21.2)” | “10 (3.1)” |
| Dry mouth | “115 (35.4)” | “29 (9.1)” |
| Insomnia (initial, middle, or unspecified) | “67 (20.6)” | “15 (4.7)” |
| Nausea | “37 (11.4)” | “2 (0.6)” |
| Urinary hesitation | “29 (8.9)” | “1 (0.3)” |
| Constipation | “17 (5.2)” | “4 (1.3)” |
| Somnolence | “17 (5.2)” | “10 (3.1)” |

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

<a id="topic-3.1.1.8.5-2"></a>

##### Treatment discontinuation due to adverse events

> “Overall, 21.2% (69/325) of participants receiving AD109 and 3.1% (10/319) of participants receiving placebo discontinued treatment due to an AE (Table 6).”
> “The primary (occurring in ≥7 participants) AEs leading to AD109 discontinuation were insomnia, urinary hesitation, and nausea (Table 6).”

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

<a id="topic-3.1.1.8.5-3"></a>

##### Adverse events leading to treatment discontinuation in two or more participants

| Event | AD109 (n = 325), n (%) |
| --- | --- |
| Insomnia | “16 (4.9)” |
| Urinary hesitation | “8 (2.5)” |
| Nausea | “7 (2.2)” |
| Erectile dysfunction or sexual dysfunction | “5 (1.5)” |
| Dry mouth | “4 (1.2)” |
| Hypertension | “3 (0.9)” |
| Palpitations | “3 (0.9)” |
| Upper abdominal pain | “2 (0.6)” |
| Feeling jittery | “2 (0.6)” |
| Urinary retention | “2 (0.6)” |

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

<a id="topic-3.1.1.8.5-4"></a>

##### Severity of adverse events and serious adverse events

> “The most common AEs were generally mild in severity (Table S4).”
> “Serious AEs were reported by 1.5% (5/325) of participants who received AD109 and 2.5% (8/319) of participants who received placebo; all were deemed by investigators to be unrelated to study medication (Table 6).”
> “In the AD109 arm, 5 participants experienced the following serious adverse events (all unrelated to AD109 treatment): 1 participant had cholelithiasis and cholestatic hepatitis, 1 participant had gastritis and bacterial pneumonia, 1 participant had asthma and chronic obstructive pulmonary disease, 1 participant had cholecystitis, and 1 participant had malignant melanoma.”
> “No deaths were reported in the trial.”

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

<a id="topic-3.1.1.8.5-5"></a>

##### Registry adverse events at the 5% reporting threshold, safety population

| Event | AD109, affected/at risk (%) | Placebo, affected/at risk (%) |
| --- | --- | --- |
| Serious adverse events, total | “5/325 (1.54%)” | “8/319 (2.51%)” |
| Other adverse events, total | “176/325 (54.15%)” | “50/319 (15.67%)” |
| Dry mouth | “115/325 (35.38%)” | “29/319 (9.09%)” |
| Nausea | “37/325 (11.38%)” | “2/319 (0.63%)” |
| Constipation | “17/325 (5.23%)” | “4/319 (1.25%)” |
| Somnolence | “17/325 (5.23%)” | “10/319 (3.13%)” |
| Middle insomnia | “38/325 (11.69%)” | “10/319 (3.13%)” |
| Initial insomnia | “30/325 (9.23%)” | “4/319 (1.25%)” |
| Urinary hesitation | “29/325 (8.92%)” | “1/319 (0.31%)” |

Source: [ClinicalTrials.gov NCT05813275 results](https://clinicaltrials.gov/study/NCT05813275?tab=results)

<a id="topic-3.1.1.8.5-6"></a>

##### Any adverse event counts in the congress abstract

> “Adverse events (AEs) were predominantly mild with ≥1 AE reported by 232 (71.4%) participants with AD109 and 151 (47.3%) with PBO.”
> “No treatment-related serious AEs were identified.”

Source: [Strollo et al. (2025c)](https://journal.chestnet.org/article/S0012-3692%2825%2905441-8/fulltext)

<a id="topic-3.1.1.8.5-7"></a>

##### Heart rate and blood pressure, safety analysis set

| Measure | AD109, mean change (SD) [n] | Placebo, mean change (SD) [n] |
| --- | --- | --- |
| Heart rate, beats/min, baseline day 1 to week 26 day 1 | “1.5 (9.8) [268]” | “−1.9 (10.1) [277]” |
| Heart rate, beats/min, baseline day 2 to week 26 day 2 | “3.6 (9.4) [267]” | “0.0 (9.2) [276]” |
| Systolic blood pressure, mm Hg, baseline day 1 to week 26 day 1 | “1.4 (11.8) [268]” | “1.7 (11.9) [277]” |
| Diastolic blood pressure, mm Hg, baseline day 1 to week 26 day 1 | “0.9 (8.0) [268]” | “−0.5 (7.7) [277]” |

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

<a id="topic-3.1.1.8.5-8"></a>

##### Heart rate of 100 beats per minute or higher at any time on treatment

> “Changes in blood pressure and heart rate were small, although a small subgroup of participants showed tachycardia while on AD109.”

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

| Measure | AD109 (n = 325), n (%) | Placebo (n = 319), n (%) | P value |
| --- | --- | --- | --- |
| Heart rate ≥100 beats/min, on study | “20 (6.3)” | “6 (1.9)” | “.006” |
| Systolic blood pressure ≥140 mm Hg, on study | “83 (26.3)” | “82 (26.5)” | “.939” |
| Diastolic blood pressure ≥90 mm Hg, on study | “65 (20.6)” | “64 (20.7)” | “.956” |

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

<a id="topic-3.1.1.8.5-9"></a>

##### Sleep architecture at week 26, post hoc analysis in the safety analysis set

| Measure | AD109 change, median (IQR) | Placebo change, median (IQR) |
| --- | --- | --- |
| Total sleep time, min | “−8.8 (−52.1 to 35.0)” | “7.5 (−27.2 to 40.0)” |
| Sleep efficiency, % | “−1.9 (−10.3 to 7.8)” | “0.6 (−5.9 to 8.1)” |
| Stage N1, % | “3.0 (−1.7 to 7.8)” | “−0.3 (−3.8 to 3.8)” |
| Stage N2, % | “7.3 (−0.8 to 13.8)” | “2.2 (−4.4 to 10.0)” |
| Stage N3, % | “−1.6 (−6.1 to 0.6)” | “−1.3 (−6.1 to 0.8)” |
| Stage REM, % | “−7.5 (−13.6 to −0.9)” | “−0.2 (−5.0 to 5.2)” |

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

> “Small changes in sleep architecture were observed consistent with the higher prevalence of insomnia.”

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

<a id="topic-3.1.1.8.5-10"></a>

##### Body mass index change at week 26

> “Changes in BMI at week 26 were small across treatment groups; median change was −0.1 kg/m2 (IQR, −1.1 to 0.6) with AD109 and 0.1 kg/m2 (IQR, −0.4 to 0.9) with placebo.”

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

<a id="topic-3.1.1.8.5-11"></a>

##### Insomnia as a reason for discontinuation and baseline insomnia assessment

> “The population studied must have been intolerant to or refused PAP therapy to enroll; thus, the trial may have been enriched with participants who may have exhibited some degree of subclinical insomnia.41 However, insomnia was not assessed in a standardized manner in this trial.”

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/)

> “Insomnia was the main reason for discontinuation in 4.9% of participants in SynAIRgy and 3% of participants in LunAIRo.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-3.1.1.8.5-12"></a>

##### Editorial comment on tolerability and long-term safety

> “Adverse events, primarily anticholinergic and stimulant-related, including dry mouth, insomnia, and urinary symptoms, were common, and treatment discontinuation occurred in 21.2% of participants.”
> “The long-term cognitive safety of chronic antimuscarinic therapy remains uncertain, with observational studies linking cumulative anticholinergic exposure to dementia risk, although causality has not been established.”

Source: [Mehra and Mokhlesi (2026)](https://academic.oup.com/ajrccm/article/212/7/1427/8679096)

<a id="heading-3.1.1.9"></a>

### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

#### Summary

- Design: 26 weeks of treatment against placebo, with polysomnography at baseline and weeks 4 and 26; no active comparator. Dose reduction was not permitted, and participants could start PAP during the trial.
- Population: adults intolerant of or refusing PAP, with a PROMIS-Fatigue T-score above 50 and a BMI cap of 40 (men) or 42 (women) kg/m2. Exclusions included clinically significant cardiovascular disease, blood pressure above 145/90 mmHg, bothersome insomnia, specified psychiatric disorders, and narrow angle glaucoma. Sites were limited to the United States and Canada, which the authors state may not represent OSA in other geographies.
- Eligibility AHI changed during enrollment: protocol version 2.0 (July 2023) required more than 5 to 45 events/h, version 5.0 (February 2024) required 10 to 45, and the publication states participants with AHI of 5 or more were enrolled first. The 2024 congress abstract described AHI4 of 5 or more, and the 2025 abstract AHI4 above 5 with no upper limit. Enrollment ran from December 20, 2023 to March 26, 2025.
- Severity mix: enrollment limits capped each AHI4 stratum at about 20% to 40%, and the authors state the population skewed toward mild-to-moderate disease, which can limit absolute effects; the editorial gives a median baseline AHI of 19.6.
- Endpoint change: protocol version 4.0 (December 2023) named the proportion with at least 50% AHI reduction as the primary endpoint. Amendment 6.0 (17 April 2025) reordered the primary and key secondary endpoints “to align with recent regulatory approvals for the treatment of OSA related to obesity”. The registry version of 2025-03-18 named the proportion of participants with reduction in AHI as the primary outcome, and the next version, submitted 2025-11-18, changed the outcome measures. The amendment postdates the registry's actual primary completion date (2025-03-10). Statistical analysis plan version 2.0 (22 April 2025) added the relative change in AHI on the log scale as an exploratory analysis.
- Estimands and missing data: the primary treatment policy analysis assumed data missing not at random (jump-to-reference multiple imputation). The supportive on-treatment estimand excluded data collected after treatment discontinuation and imputed missing values by last observation carried forward; it included 260 participants on AD109 and 296 on placebo, against 302 and 313 in the treatment policy set. The topline release reported the on-treatment relative reduction (55.6%) beside the treatment policy primary result (p=0.001).
- Analysis-set exclusions: 22 participants (16 AD109, 6 placebo) at site 1416, terminated for Good Clinical Practice noncompliance, and 7 participants in the exploratory GLP-1 receptor agonist cohort were excluded from efficacy analyses; that cohort's analyses were not reported because of low enrollment.
- Discontinuation: treatment discontinuation before 26 weeks was 34.3% with AD109 and 16.3% with placebo in the publication, which the authors state likely diminished the observed benefit; the prospectus reports 34.6% and 16.5% at month 6 in the main cohort. Treatment discontinuation due to adverse events was 21.2% and 3.1%; study withdrawal due to adverse events in the registry was 4 and 1 participants.
- Hierarchical testing: under the treatment policy estimand, PROMIS-Fatigue (P = .059) did not reach significance, so formal testing ended before hypoxic burden, and the responder endpoint was not significant (P = .182).
- Patient-reported outcomes: the authors cite a placebo response in both arms and possible expectation bias, and state insomnia was not assessed in a standardized manner although the PAP-intolerant population may have been enriched for subclinical insomnia.
- Clinical meaningfulness: at the pre-NDA meeting the FDA gave feedback on the clinical meaningfulness of the primary endpoint results and the limitations of the PROs, and indicated additional analyses and justification may be needed. The editorial states the clinical significance of the placebo-adjusted reduction of about 4 events per hour is uncertain as a continuous measure, and that durability, long-term safety, and effects on cardiovascular events require further study.
- Sponsor: the prospectus describes SynAIRgy as a trial the company conducted.

Source: [Strollo et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13318230/); [Taranto-Montemurro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12490522/); [Apnimed SynAIRgy protocol (2025)](https://cdn.clinicaltrials.gov/large-docs/75/NCT05813275/Prot_000.pdf); [Apnimed SynAIRgy statistical analysis plan (2025)](https://cdn.clinicaltrials.gov/large-docs/75/NCT05813275/SAP_001.pdf); [ClinicalTrials.gov NCT05813275](https://clinicaltrials.gov/study/NCT05813275); [ClinicalTrials.gov NCT05813275 version 22](https://clinicaltrials.gov/study/NCT05813275?tab=history&a=22); [ClinicalTrials.gov NCT05813275 results](https://clinicaltrials.gov/study/NCT05813275?tab=results); [Strollo et al. (2024)](https://academic.oup.com/sleep/article/47/Supplement_1/A233/7654816); [Strollo et al. (2025b)](https://academic.oup.com/sleep/article/48/Supplement_1/A339/8134797); [Apnimed SynAIRgy topline release (2025)](https://apnimed.com/article/ad109phase3toplineresults/); [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm); [Mehra and Mokhlesi (2026)](https://academic.oup.com/ajrccm/article/212/7/1427/8679096)

## Related pages
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Terms and abbreviations](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations.md)
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Product information and disease description](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Clinical evidence](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Economic information and modeling report](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: References](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references.md)
